First Time Loading...

Beijing Strong Biotechnologies Inc
SZSE:300406

Watchlist Manager
Beijing Strong Biotechnologies Inc Logo
Beijing Strong Biotechnologies Inc
SZSE:300406
Watchlist
Price: 17.23 CNY 0.7% Market Closed
Updated: Jun 1, 2024

Beijing Strong Biotechnologies Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beijing Strong Biotechnologies Inc
Other Current Liabilities Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Strong Biotechnologies Inc
SZSE:300406
Other Current Liabilities
¥113.3m
CAGR 3-Years
3%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Current Liabilities
¥1.5B
CAGR 3-Years
-7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Current Liabilities
¥728.3m
CAGR 3-Years
39%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Current Liabilities
¥1.9B
CAGR 3-Years
53%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Current Liabilities
¥938.7m
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
43%
Imeik Technology Development Co Ltd
SZSE:300896
Other Current Liabilities
¥110.8m
CAGR 3-Years
51%
CAGR 5-Years
50%
CAGR 10-Years
N/A

See Also

What is Beijing Strong Biotechnologies Inc's Other Current Liabilities?
Other Current Liabilities
113.3m CNY

Based on the financial report for Mar 31, 2024, Beijing Strong Biotechnologies Inc's Other Current Liabilities amounts to 113.3m CNY.

What is Beijing Strong Biotechnologies Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
18%

Over the last year, the Other Current Liabilities growth was 8%. The average annual Other Current Liabilities growth rates for Beijing Strong Biotechnologies Inc have been 3% over the past three years , 18% over the past five years .